|
HC
n=18
|
Stable
n=14
|
p Value*
|
Stable
n=19
|
p
Value†
|
Age (years) |
64 ± 15 |
62 ± 12 |
0.63 |
64 ± 15 |
0.92 |
BMI (kg/m2) |
30 ± 8 |
27 ± 6 |
0.27 |
27 ± 7 |
0.24 |
Male |
11 (61%) |
10 (71%) |
0.54 |
12 (63%) |
0.90 |
White |
9 (50 %) |
8 (57%) |
0.69 |
11 (58%) |
0.63 |
Past Medical History |
Past Medical History |
Past Medical History |
Past Medical History |
Past Medical History |
Past Medical
History |
Hypertension |
14 (78%) |
9 (64%) |
0.40 |
13 (68%) |
0.19 |
Systolic HF |
2 (11%) |
3 (21%) |
0.43 |
5 (26%) |
0.24 |
Diastolic HF |
2 (11%) |
4 (29%) |
0.21 |
9 (47%) |
0.02 |
Coronary Artery Disease |
2 (11%) |
3 (21%) |
0.43 |
8 (42%) |
0.03 |
Atrial Fibrillation |
1 (6%) |
3 (21%) |
0.18 |
5 (26%) |
0.09 |
Diabetes |
10 (56%) |
4 (29%) |
0.13 |
6 (32%) |
0.14 |
COPD |
3 (17%) |
2 (14%)
|
0.85 |
7 (37%) |
0.17 |
Echocardiography |
Echocardiography |
Echocardiography |
Echocardiography |
Echocardiography |
Echocardiography |
LVEF |
55 ± 14 |
58 ± 10 |
0.62 |
44 ± 17 |
0.07 |
Diastolic Dysfunction |
4 (22%) |
3 (30%) |
0.78 |
11 (92%) |
0.0001 |
LVIDd |
4.7 ± 0.8 |
4.9 ± 0.3 |
0.41 |
5.3 ± 1.4 |
0.16 |
RV Dysfunction |
5 (28%) |
1 (10%) |
0.21 |
1 (10%) |
0.21 |
TAPSE |
2.0 ± 0.4 |
2.2 ± 0.5 |
0.38 |
2.0 ± 0.4 |
0.96 |
LA Dilation |
2 (11%) |
2 (25%) |
0.65 |
3 (27%) |
0.54 |
Mitral Regurgitation |
3 (17%) |
4 (29%) |
0.42 |
5 (26%) |
0.48 |
Tricuspid Regurgitation |
5 (28%) |
6 (43%) |
0.37 |
7 (37%) |
0.56 |
Aortic Regurgitation |
2 (11%) |
0 |
0.20 |
4 (21%) |
0.41 |
Pericardial Effusion |
4 (22%) |
3 (21%) |
0.96 |
3 (16%) |
0.62 |
Vital Signs and Laboratory Values at ATA Onset |
Vital Signs and
Laboratory Values at ATA Onset |
Vital Signs and Laboratory Values at
ATA Onset |
Vital Signs and Laboratory Values at ATA Onset |
Vital Signs
and Laboratory Values at ATA Onset |
Vital Signs and Laboratory Values
at ATA Onset |
Heart Rate Change |
50 ± 22 |
35 ± 24 |
0.09 |
39 ± 25 |
0.18 |
MAP |
74 ± 16 |
89 ± 10 |
0.004 |
82 ± 15 |
0.12 |
Sodium |
140 ± 6 |
137 ± 5 |
0.34 |
138 ± 8 |
0.49 |
Potassium |
4.5 ± 0.4 |
4.2 ± 0.5 |
0.04 |
4.1 ± 0.6 |
0.02 |
Magnesium |
2.0 ± 0.4 |
2.2 ± 0.4 |
0.21 |
2.0 ± 0.5 |
0.99 |
Creatinine |
2.2 ± 1.4 |
1.8 ± 0.8 |
0.46 |
2.2 ± 2.4 |
0.90 |
Inpatient Therapies at ATA Onset |
Inpatient Therapies at ATA Onset |
Inpatient Therapies at ATA Onset |
Inpatient Therapies at ATA Onset |
Inpatient Therapies at ATA Onset |
Inpatient Therapies at ATA
Onset |
Mechanical Ventilation |
18 (100%) |
8 (57%) |
0.002 |
3 (16%) |
0.0001 |
Prone Positioning |
2 (11%) |
0 |
0.20 |
0 |
0.14 |
Vasopressors Use |
15 (83%) |
3 (21%) |
0.0001 |
2 (11%) |
0.0001 |
CRRT |
9 (50%) |
4 (29%) |
0.22 |
4 (21%) |
0.07 |
Ventilation Parameters at ATA Onset ‡
|
Ventilation
Parameters at ATA Onset ‡
|
Ventilation Parameters at
ATA Onset ‡
|
Ventilation Parameters at ATA Onset
‡
|
Ventilation Parameters at ATA Onset
‡
|
Ventilation Parameters at ATA Onset
‡
|
PEEP |
10 ± 4 |
5 ± 4 |
0.005 |
1 ± 3 |
0.0001 |
Plateau Pressure |
25 ± 7 |
23 ± 5 |
0.58 |
27 ± 4 |
0.75 |
FiO2 (%) |
57 ± 17 |
46 ± 15 |
0.06 |
29 ± 6 |
0.0001 |
Outcomes |
Outcomes |
Outcomes |
Outcomes |
Outcomes |
Outcomes |
Death |
12 (67%) |
4 (29%) |
0.03 |
5 (26%) |
0.01 |